Episoder
-
What were the biggest takeaways from ESMO 2023 related to TNBC and IBC? Tune in to hear experts Drs Kevin Kalinsky and Filipa Lynce discuss.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991259). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Inflammatory Breast Cancer: What You Should Know https://www.medscape.com/viewarticle/778334
Incidence, Characteristics, and Management of Central Nervous System Metastases in Patients With Inflammatory Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36210737/
Inflammatory Breast Cancer Cells Are Characterized by Abrogated Tgfβ1-Dependent Cell Motility and SMAD3 Activity https://pubmed.ncbi.nlm.nih.gov/32043194/
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States https://pubmed.ncbi.nlm.nih.gov/36409824/
Whole-Genome Sequencing of Phenotypically Distinct Inflammatory Breast Cancers Reveals Similar Genomic Alterations to Non-inflammatory Breast Cancers https://pubmed.ncbi.nlm.nih.gov/33902690/
OncoPanel http://cancergeneticslab.ca/genes/oncopanel/
TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI) https://classic.clinicaltrials.gov/ct2/show/NCT05795101
Phase 2 Study of Response-Guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer: Results From the NeoSTAR Trial https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.512
The I-SPY Trials https://www.ispytrials.org/
381O First-in-Human/Phase I Trial of HS-20089, a B7-H4 ADC, in Patients With Advanced Solid Tumors https://www.annalsofoncology.org/article/S0923-7534(23)01394-7/fulltext
660MO - First-in-Human Study of SGN-B7H4V, a B7-H4-Directed Vedotin ADC, in Patients With Advanced Solid Tumors: Preliminary Results of a Phase I Study (SGNB7H4V-001) https://oncologypro.esmo.org/meeting-resources/esmo-congress/first-in-human-study-of-sgn-b7h4v-a-b7-h4-directed-vedotin-adc-in-patients-with-advanced-solid-tumors-preliminary-results-of-a-phase-i-study-sg
The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma https://pubmed.ncbi.nlm.nih.gov/37871703/
-
Join Drs Kevin Kalinsky and Jennifer Litton as they discuss hereditary breast cancer, genetic testing, and therapeutic implications.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4
PARP and PARG Inhibitors in Cancer Treatment https://pubmed.ncbi.nlm.nih.gov/32029455/
BRCA1 and BRCA2 Mutations https://www.ncbi.nlm.nih.gov/books/NBK470239/
Iniparib Plus Chemotherapy in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/21208101/
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant https://pubmed.ncbi.nlm.nih.gov/31461380/
ER/PgR Testing in Breast Cancer Clinical Practice Guidelines (ASCO/CAP, 2020) https://reference.medscape.com/viewarticle/924542
Pathological Complete Response in Neoadjuvant Treatment of High-risk Early-stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry https://www.fda.gov/media/83507/download
Adjuvant Olaparib for Patients With BRCA1- or BRCA2-mutated Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34081848/
PALB2 Partner and Localizer of BRCA2 https://www.ncbi.nlm.nih.gov/gene/79728
Pre-specified Event Driven Analysis of Overall Survival (OS) in the OlympiA Phase III Trial of Adjuvant Olaparib (OL) in Germline BRCA1/2 Mutation (gBRCAm) Associated Breast Cancer https://oncologypro.esmo.org/meeting-resources/esmo-virtual-plenary-resources/olympia-phase-iii-pre-specified-event-driven-analysis-of-overall-survival-of-olaparib-in-gbrcam-breast-cancer
Pembrolizumab for Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/
Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/28578601/
Talazoparib in Patients With Advanced Breast Cancer and a Germline BRCA Mutation https://pubmed.ncbi.nlm.nih.gov/30110579/
Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study https://pubmed.ncbi.nlm.nih.gov/29045554/
RAD51 Recombinase https://www.ncbi.nlm.nih.gov/gene/5888
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/34068084/
Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq
Tissue-agnostic Drug Approvals: How Does This Apply to Patients With Breast Cancer? https://pubmed.ncbi.nlm.nih.gov/34518552/
-
Manglende episoder?
-
What does the cutting edge of radiation oncology look like for treating triple-negative breast cancer? Tune in to hear experts Drs Kevin Kalinsky and Reshma Jagsi discuss.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4
A Review of the Abscopal Effect in the Era of Immunotherapy https://pubmed.ncbi.nlm.nih.gov/36321062/
The Impact of Radiation-induced DNA Damage on cGAS-STING-mediated Immune Responses to Cancer https://pubmed.ncbi.nlm.nih.gov/33238631/
Gray (Gy) https://www.nrc.gov/reading-rm/basic-ref/glossary/gray-gy.html
Event-free Survival With Pembrolizumab in Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35139274/
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer https://clinicaltrials.gov/study/NCT02954874
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) https://clinicaltrials.gov/study/NCT04443348
Translational Breast Cancer Research Consortium (TBCRC) https://tbcrc.org/
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/34900718/
SWOG Cancer Research Network https://www.swog.org/
BRCA1 and BRCA2 Mutations https://www.ncbi.nlm.nih.gov/books/NBK470239/
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study https://pubmed.ncbi.nlm.nih.gov/29558281/
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer https://clinicaltrials.gov/study/NCT03598257
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
ER/PgR Testing in Breast Cancer Clinical Practice Guidelines (ASCO/CAP, 2020) https://reference.medscape.com/viewarticle/924542
Oncotype DX Breast Recurrence Score®: A Review of Its Use in Early-stage Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32613290/
Regional Radiotherapy in Biomarker Low-risk Node Positive and T3N0 Breast Cancer (TAILOR RT) https://classic.clinicaltrials.gov/ct2/show/NCT03488693
Postoperative Radiotherapy in High-risk Premenopausal Women With Breast Cancer Who Receive Adjuvant Chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial https://pubmed.ncbi.nlm.nih.gov/9395428/
Postoperative Radiotherapy in High-risk Postmenopausal Breast-cancer Patients Given Adjuvant Tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10335782/
Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/23484825/
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-risk, Node-positive Breast Cancer Enrolled in the SWOG S1007 Trial https://pubmed.ncbi.nlm.nih.gov/37410451/
-
Join experts Drs Kevin Kalinsky and Priyanka Sharma as they discuss their current approach to neoadjuvant therapy in triple negative breast cancer and how the SCARLET trial might change that.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991256). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Pembrolizumab for Early Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/
Clinical and Biomarker Results of Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer (TNBC) (NeoPACT) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.513
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35044810/
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 https://pubmed.ncbi.nlm.nih.gov/37308117/
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab https://classic.clinicaltrials.gov/ct2/show/NCT05812807
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer https://clinicaltrials.gov/study/NCT05929768
Neoadjuvant Atezolizumab in Combination With Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy Versus Placebo and Chemotherapy in Patients With Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/32966830/
Adjuvant Capecitabine for Breast Cancer After Preoperative Chemotherapy https://pubmed.ncbi.nlm.nih.gov/28564564/
Impact of Neoadjuvant Chemotherapy on Axillary Nodal Involvement in Patients With Clinically Node Negative Triple Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/25266871/
Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): A Multicentre, Open-Label, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30413379/
-
Join experts Drs Kevin Kalinsky and Aditya Bardia as they discuss utilizing antibody-drug conjugates in clinic. What is currently available? What are the possible side effects? Tune in to find out.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991254). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4
Introduction to Antibody-drug Conjugates https://pubmed.ncbi.nlm.nih.gov/34842621/
Antibody-drug Conjugates Targeting TROP-2: Clinical Development in Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36302269/
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
HER2 Status in Breast Cancer: Changes in Guidelines and Complicating Factors for Interpretation https://pubmed.ncbi.nlm.nih.gov/31693827/
Whole-exome Sequencing Identifies Somatic Mutations and Intratumor Heterogeneity in Inflammatory Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34075047/
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/
Trastuzumab Deruxtecan in Previously Treated HER2-low Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35665782/
TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2-metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32223649/
Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/
Scalp Cooling to Prevent Chemotherapy-induced Alopecia https://pubmed.ncbi.nlm.nih.gov/32622629/
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) https://www.clinicaltrials.gov/search?term=NCT03401385
Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-low Breast Cancer https://ascopost.com/issues/january-25-2023/neoadjuvant-t-dxd-demonstrates-activity-in-phase-ii-study-of-patients-with-her2-low-breast-cancer/
Sacituzumab Govitecan in TNBC (NeoSTAR) https://clinicaltrials.gov/study/NCT04230109
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) https://www.clinicaltrials.gov/study/NCT05629585
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) https://www.clinicaltrials.gov/study/NCT05633654
-
Join experts Drs Kevin Kalinsky and Heather McArthur as they discuss the latest studies guiding their decisions when treating patients with TNBC in clinic.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991253). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Pembrolizumab Plus Chemotherapy in Advanced Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35857659/
Pembrolizumab for Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/
Event-free Survival With Pembrolizumab in Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35139274/
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab https://classic.clinicaltrials.gov/ct2/show/NCT05812807
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/
Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2023-00614&r=1
Adjuvant Capecitabine for Breast Cancer After Preoperative Chemotherapy https://pubmed.ncbi.nlm.nih.gov/28564564/
A Phase Ib Trial of Pembrolizumab Plus Paclitaxel or Flat-dose Capecitabine in 1st/2nd Line Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37344474/
Adjuvant Olaparib for Patients With BRCA1- or BRCA2-mutated Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34081848/
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer https://classic.clinicaltrials.gov/ct2/show/NCT02954874
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer (IMpassion030) https://classic.clinicaltrials.gov/ct2/show/NCT03498716
Neoadjuvant Atezolizumab in Combination With Sequential Nab-paclitaxel and Anthracycline-based Chemotherapy Versus Placebo and Chemotherapy in Patients With Early-stage Triple-negative Breast Cancer (IMpassion031): A Randomised, Double-blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/32966830/
LBA1 - Final Analysis of the Placebo-controlled Randomised Phase 3 IMpassion031 Trial Evaluating Neoadjuvant Atezolizumab (Atezo) Plus Chemotherapy (CT) Followed by Open-label Adjuvant Atezo in Patients (pts) With Early-stage Triple-negative Breast Cancer (eTNBC) https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress/final-analysis-of-the-placebo-controlled-randomised-phase-3-impassion031-trial-evaluating-neoadjuvant-atezolizumab-atezo-plus-chemotherapy-ct-f
The I-SPY Trials https://www.ispytrials.org/
BEGONIA: Phase 1b/2 Study of Durvalumab (D) Combinations in Locally Advanced/Metastatic Triple-negative Breast Cancer (TNBC)—Initial Results From Arm 1, D+Paclitaxel (P), and Arm 6, D+Trastuzumab Deruxtecan (T-DXd). https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.1023
